Context Therapeutics Management
Management criteria checks 2/4
Context Therapeutics' CEO is Martin Lehr, appointed in Jan 2015, has a tenure of 10.92 years. total yearly compensation is $1.01M, comprised of 50.1% salary and 49.9% bonuses, including company stock and options. directly owns 1.18% of the company’s shares, worth $1.24M. The average tenure of the management team and the board of directors is 3.9 years and 4.8 years respectively.
Key information
Martin Lehr
Chief executive officer
US$1.0m
Total compensation
| CEO salary percentage | 50.07% |
| CEO tenure | 10.9yrs |
| CEO ownership | 1.2% |
| Management average tenure | 3.9yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
We're Hopeful That Context Therapeutics (NASDAQ:CNTX) Will Use Its Cash Wisely
Dec 19
Here's Why We're Not Too Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Situation
Aug 03We're Not Very Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Mar 30We Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business Growth
Aug 15We're A Little Worried About Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Mar 27Here's Why Context Therapeutics (NASDAQ:CNTX) Must Use Its Cash Wisely
Sep 28Will Context Therapeutics (NASDAQ:CNTX) Spend Its Cash Wisely?
Jun 05Context to focus on ELONA trial, CLDN6 program, extends cash runway into 1Q24
Sep 27We're Keeping An Eye On Context Therapeutics' (NASDAQ:CNTX) Cash Burn Rate
Sep 15Context Therapeutics GAAP EPS of -$0.25 in-line
Aug 11Context Therapeutics, Menarini to collaborate on breast cancer treatment combo trial
Aug 02Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth
May 28Context Therapeutics: A New Biotech Issue With A Low Valuation And Significant Potential
Nov 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$26m |
| Jun 30 2025 | n/a | n/a | -US$34m |
| Mar 31 2025 | n/a | n/a | -US$28m |
| Dec 31 2024 | US$1m | US$506k | -US$27m |
| Sep 30 2024 | n/a | n/a | -US$30m |
| Jun 30 2024 | n/a | n/a | -US$19m |
| Mar 31 2024 | n/a | n/a | -US$21m |
| Dec 31 2023 | US$861k | US$492k | -US$24m |
| Sep 30 2023 | n/a | n/a | -US$21m |
| Jun 30 2023 | n/a | n/a | -US$19m |
| Mar 31 2023 | n/a | n/a | -US$18m |
| Dec 31 2022 | US$1m | US$477k | -US$15m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | -US$12m |
| Mar 31 2022 | n/a | n/a | -US$13m |
| Dec 31 2021 | US$2m | US$291k | -US$10m |
| Sep 30 2021 | n/a | n/a | -US$8m |
| Jun 30 2021 | n/a | n/a | -US$7m |
| Mar 31 2021 | n/a | n/a | -US$648k |
| Dec 31 2020 | US$250k | US$250k | US$1m |
| Dec 31 2019 | US$250k | US$250k | -US$6m |
Compensation vs Market: Martin's total compensation ($USD1.01M) is above average for companies of similar size in the US market ($USD577.67K).
Compensation vs Earnings: Martin's compensation has increased whilst the company is unprofitable.
CEO
Martin Lehr (41 yo)
Mr. Martin A. Lehr serves as Independent Director of Praesidia Biotherapeutics, Inc. He is the Co-founder, President, Chief Executive Officer and Director of Context Therapeutics Inc., since 2015. Mr. Lehr...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 10.9yrs | US$1.01m | 1.18% $ 1.2m | |
| CFO & Treasurer | 4.1yrs | US$698.97k | 0.087% $ 88.8k | |
| Chief Legal Officer & Corporate Secretary | 4.7yrs | US$670.65k | 0.089% $ 91.0k | |
| Senior Vice President of Operations | 3.9yrs | no data | no data | |
| Associate Director of Accounting | less than a year | no data | no data | |
| Senior Vice President of Technical Operations | less than a year | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
Experienced Management: CNTX's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 10.9yrs | US$1.01m | 1.18% $ 1.2m | |
| Independent Director | 4.8yrs | US$96.70k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$100.69k | 0% $ 0 | |
| Independent Director | 7yrs | US$81.82k | 0.0038% $ 3.9k | |
| Independent Director | 1.3yrs | US$50.89k | no data | |
| Independent Director | 1.3yrs | US$50.41k | no data |
Experienced Board: CNTX's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/24 18:21 |
| End of Day Share Price | 2025/12/23 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Context Therapeutics Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Li Wang Watsek | Cantor Fitzgerald & Co. |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |
| Jason Kolbert | D. Boral Capital LLC. |